Chapter 69. Renal Dysfunction

  1. Salim Yusuf DPhil, FRCPC, FRSC Research Chair Professor of Medicine Director Vice President Research3,4,5,
  2. John A Cairns MD, FRCPC Professor of Medicine Former Dean6,
  3. A John Camm MD British Heart Foundation Professor Head of Cardiac7,
  4. Ernest L Fallen MD, FRCPC Professor Emeritus8 and
  5. Bernard J Gersh MB, ChB, DPhil Consultant Professor of Medicine9
  1. Johannes F E Mann MD Professor Head1 and
  2. Ernesto L Schiffrin MD, PhD, FRSC, FRCPC, FACP Physician-in-Chief Chair2

Published Online: 21 MAY 2010

DOI: 10.1002/9781444309768.ch69

Evidence-Based Cardiology, Third Edition

Evidence-Based Cardiology, Third Edition

How to Cite

Mann, J. F. E. and Schiffrin, E. L. (2009) Renal Dysfunction, in Evidence-Based Cardiology, Third Edition (eds S. Yusuf, J. A. Cairns, A. J. Camm, E. L. Fallen and B. J. Gersh), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444309768.ch69

Editor Information

  1. 3

    McMaster University, Canada

  2. 4

    Population Health Research Institute, McMaster University, Hamilton Health Sciences, Canada

  3. 5

    Hamilton Health Sciences, Hamilton, Ontario, Canada

  4. 6

    Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

  5. 7

    St George's University of London, London, UK

  6. 8

    McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada

  7. 9

    Mayo Clinic College of Medicine, Rochester, MN, USA

Author Information

  1. 1

    Friedrich Alexander University of Erlangen, Department of Nephrology and Hypertension, Schwabing General Hospital, Ludwig Maximilians University, Munich, Germany

  2. 2

    Department of Medicine, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada

Publication History

  1. Published Online: 21 MAY 2010
  2. Published Print: 13 NOV 2009

ISBN Information

Print ISBN: 9781405159258

Online ISBN: 9781444309768

SEARCH

Keywords:

  • renal dysfunction - chronic kidney disease (CKD);
  • CKD - renal disease lasting more than three months, with renal damage signs;
  • kidney-related cardiovascular risk factors - serum creatinine;
  • urinary protein excretion and kidney disease evaluation;
  • renal dysfunction associated cardiovascular risk impact;
  • micro - and macroalbuminuria and cardiovascular risk;
  • RAS - renin-angiotensin system;
  • RAS inhibitors' adverse effects - acute renal failure

Summary

This chapter contains sections titled:

  • Definition of chronic kidney disease

  • When to measure eGFR and urinary protein excretion?

  • Population-wide impact of cardiovascular risk associated with renal dysfunction

  • Why are low GFR and proteinuria risk factors for vascular disease?

  • Implications for therapy

  • References